Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
Abstract The prognosis of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) remained unsatisfactory currently, more anti-HER2 agents are needed. Here we report a phase I study that evaluated the safety, activity, and biomarkers of LZM005, a HER2 antibody, used a...
Main Authors: | Cong Xue, Haifeng Li, Herui Yao, Ying Lin, Xin An, Meiting Chen, Riqing Huang, Lu Li, Anqi Hu, Mengqian Ni, Lulu Zhang, Wei Yang, Zhonghui Xu, Su Li, Yanxia Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-12-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-022-00501-2 |
Similar Items
-
A Novel Ferroptosis-Related Gene Signature Predicts Overall Survival of Breast Cancer Patients
by: Haifeng Li, et al.
Published: (2021-02-01) -
Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study
by: Riqing Huang, et al.
Published: (2023-10-01) -
The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
by: Zihong Wu, et al.
Published: (2023-03-01) -
HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01) -
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
by: Yabing Zheng, et al.
Published: (2023-12-01)